The SNMMI (The Society of Nuclear Medicine and Molecular Imaging) 2024 Therapeutics Conference is coming to Bethesda, MD, on September 19~21, 2024, at the Bethesda North Marriott Hotel and Conference Center.

This exciting event will bring together leaders in radiopharmaceutical therapy to explore the latest innovations and advancements in the field as well as practical clinical information about running your therapy practice. With two-and-a-half days of informative sessions, an extensive table-top exhibit, and a variety of networking opportunities, you'll have the chance to connect with colleagues, learn from experts, and gain valuable insights into enhancing the practice of radiopharmaceutical therapies.

VitsGen Therapeutics is developing targeted radiopharmaceutical medicines to treat cancer since 2021. Vitsgen targeted radiopharmaceuticals are designed to deliver calculated doses of radiation to targeted tumors without impacting healthy tissue and vital organs.

We are changing the way how cancer is treated and creating medicines for the treatment of various types of solid tumors to address unmet clinical needs.

We fully believe targeted radiopharmaceuticals have great promise to improve the lives of cancer patients.

Welcome to visit our booth (#13) or contact us (BD@vitsgen.com) to learn more about our full portfolio of technology and pipeline for collaboration. We look forward to seeing you soon!

VitsGen's portfolio of targeted radiopharmaceutical targets includes:

►Prostate-specific membrane antigen

►Fibroblast activation protein-α

►Carbonic Anhydrase IX, CAIX